Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Cristofanilli

Showing results (61-70 of 438) with videos related to

Pageof 44
Sort By:
The Oncologist|April 17, 2003
Update on the management of inflammatory breast cancerMassimo Cristofanilli, Aman U Buzdar, Gabriel N Hortobágyi
Personalized Medicine|May 23, 2018
Molecular dissection of cancers - another piece in the puzzle to better assess, and treat, disease using biomarkers that correlate with disease type and stageFelix Frueh, Amalia Issa, Eleni Andreopoulou, et al.
Expert Opinion on Medical Diagnostics|March 19, 2013
The role of circulating tumor cells in breast cancer diagnosis and prediction of therapy responseJames M Reuben, Savitri Krishnamurthy, Wendy Woodward, et al.
Current Opinion in Oncology|July 16, 2024
Modeling the management of patients with human epidermal growth factor receptor 2-positive breast cancer with liquid biopsy: the future of precision medicineEleonora Nicolò, Caterina Gianni, Giuseppe Curigliano, et al.
Cancer|May 16, 2007
Manipulating the chemokine-chemokine receptor network to treat cancerPier A Ruffini, Paolo Morandi, Neslihan Cabioglu, et al.
BMJ Case Reports|June 21, 2012
Recurrent granulomatous mastitis mimicking inflammatory breast cancerAhmet Bahadir Ergin, Massimo Cristofanilli, Hamed Daw, et al.
British Journal of Cancer|March 11, 2022
Circulating tumour cells in the -omics era: how far are we from achieving the 'singularity'?Tanvi H Visal, Petra den Hollander, Massimo Cristofanilli, et al.
Cancers|January 21, 2023
Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with NiclosamideUdayan Bhattacharya, Mohammad Kamran, Maroua Manai, et al.
Breast Cancer Research : BCR|February 22, 2016
Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent mannerJoshua Ogony, Hye Joung Choi, Asona Lui, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancerHamouda Boussen, Massimo Cristofanilli, Tal Zaks, et al.
Pageof 44

Showing results (61-70 of 438) with videos related to

Sort By:
Pageof 44
The Oncologist|April 17, 2003
Update on the management of inflammatory breast cancerMassimo Cristofanilli, Aman U Buzdar, Gabriel N Hortobágyi
Personalized Medicine|May 23, 2018
Molecular dissection of cancers - another piece in the puzzle to better assess, and treat, disease using biomarkers that correlate with disease type and stageFelix Frueh, Amalia Issa, Eleni Andreopoulou, et al.
Expert Opinion on Medical Diagnostics|March 19, 2013
The role of circulating tumor cells in breast cancer diagnosis and prediction of therapy responseJames M Reuben, Savitri Krishnamurthy, Wendy Woodward, et al.
Current Opinion in Oncology|July 16, 2024
Modeling the management of patients with human epidermal growth factor receptor 2-positive breast cancer with liquid biopsy: the future of precision medicineEleonora Nicolò, Caterina Gianni, Giuseppe Curigliano, et al.
Cancer|May 16, 2007
Manipulating the chemokine-chemokine receptor network to treat cancerPier A Ruffini, Paolo Morandi, Neslihan Cabioglu, et al.
BMJ Case Reports|June 21, 2012
Recurrent granulomatous mastitis mimicking inflammatory breast cancerAhmet Bahadir Ergin, Massimo Cristofanilli, Hamed Daw, et al.
British Journal of Cancer|March 11, 2022
Circulating tumour cells in the -omics era: how far are we from achieving the 'singularity'?Tanvi H Visal, Petra den Hollander, Massimo Cristofanilli, et al.
Cancers|January 21, 2023
Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with NiclosamideUdayan Bhattacharya, Mohammad Kamran, Maroua Manai, et al.
Breast Cancer Research : BCR|February 22, 2016
Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent mannerJoshua Ogony, Hye Joung Choi, Asona Lui, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancerHamouda Boussen, Massimo Cristofanilli, Tal Zaks, et al.
Pageof 44